<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01549600</url>
  </required_header>
  <id_info>
    <org_study_id>2011063</org_study_id>
    <nct_id>NCT01549600</nct_id>
  </id_info>
  <brief_title>Comparison of Psyllium and Microcrystalline Cellulose on Glycemic Measures in Subjects With Impaired Fasting Glucose</brief_title>
  <official_title>A Randomized, Controlled Study To Compare the Effects of 2 Types of Dietary Fiber, Psyllium and Microcrystalline Cellulose, on Glycemic Measures in Subjects With Pre-type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Procter and Gamble</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Procter and Gamble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of this study is to compare the effects of 2 types of dietary fiber, psyllium and&#xD;
      microcrystalline cellulose (MCC), on glycemic measures in subjects with impaired fasting&#xD;
      glucose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted at a single study center. Approximately 40 subjects with&#xD;
      pre-type 2 diabetes will be enrolled and randomized in this study.&#xD;
&#xD;
      This 22-week study consists of 3 periods: an 8-week treatment period (Visits 2-4), a 6-week&#xD;
      washout period, and an 8-week treatment period (Visits 5-7).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fasting serum glucose</measure>
    <time_frame>8 weeks</time_frame>
    <description>mean change from baseline in fasting serum glucose at 8 weeks</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Impaired Fasting Glucose</condition>
  <arm_group>
    <arm_group_label>psyllium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5.1 g psyllium husk in at least 8 ounces of water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microcrsytalline Cellulose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.18 g Microcrystalline Cellulose in at least 8 ounces of water, taken twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>psyllium</intervention_name>
    <description>1 level tablespoon (~ 5.1 g psyllium husk in the psyllium product) mixed with at least 8 ounces of water, taken twice daily</description>
    <arm_group_label>psyllium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Microcrystalline Cellulose</intervention_name>
    <description>1 level tablespoon (~ 1.18 g MCC in the MCC product) mixed with at least 8 ounces of water, taken twice a day</description>
    <arm_group_label>Microcrsytalline Cellulose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  be male or female,&#xD;
&#xD;
          -  at least 18 years of age&#xD;
&#xD;
          -  in generally good health for the pre-type 2 diabetes population;&#xD;
&#xD;
          -  if female, be postmenopausal or if of child-bearing capacity agree to use an adequate&#xD;
             form of contraception&#xD;
&#xD;
          -  have not used any psyllium containing products within the past 3 months;&#xD;
&#xD;
          -  be willing to refrain from taking any psyllium containing products during the study;&#xD;
&#xD;
          -  be willing to maintain a lifestyle habits for the duration of the study;&#xD;
&#xD;
          -  have a fasting serum glucose of 110 - 125 mg/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  if female, are pregnant or nursing (lactating);&#xD;
&#xD;
          -  have a history of diabetes (diagnosis) or is currently taking medications for diabetes&#xD;
&#xD;
          -  participated in a clinical drug study or used investigational drug during the previous&#xD;
             30 days;&#xD;
&#xD;
          -  have symptoms and signs suggestive of significant underlying disease, or acute onset&#xD;
             of new symptoms and signs of major organ disease, that could become unstable during&#xD;
             the trial requiring urgent medical intervention&#xD;
&#xD;
          -  have evidence of or treatment history of malignancy within the previous 5 years;&#xD;
&#xD;
          -  currently alcohol dependent;&#xD;
&#xD;
          -  used anti-psychotics in the previous 3 months;&#xD;
&#xD;
          -  used systemic steroidal agents within the last 30 days;&#xD;
&#xD;
          -  had used oral or systemic antibiotics or any over-the-counter (OTC) bactericidal&#xD;
             medication (eg, bismuth salts) within the last 30 days;&#xD;
&#xD;
          -  has been taking any medication that may affect blood glucose or GI motility (eg,&#xD;
             calcium channel blockers, beta blockers, antimuscarinics, salicylates etc.) for less&#xD;
             than 30 days or 5 times the half life of the drug (need to be stable on the&#xD;
             medication);&#xD;
&#xD;
          -  have evidence of immunodeficiency including subjects currently taking systemic&#xD;
             corticosteroids or immunosuppressive drugs&#xD;
&#xD;
          -  have a major psychiatric disorder, including major depression, psychoses, alcohol or&#xD;
             substance abuse within the past 2 years;&#xD;
&#xD;
          -  has a known sensitivity or allergy to any components of study products, including&#xD;
             psyllium and aspartame (see Section 3.5.3);&#xD;
&#xD;
          -  were previously screened (ie, Visit 1 procedures) for participation in this study and&#xD;
             failed to meet entry criteria;&#xD;
&#xD;
          -  have difficulty swallowing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John McRorie, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Procter and Gamble</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Feinglos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Surwit, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>March 6, 2012</study_first_submitted>
  <study_first_submitted_qc>March 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2012</study_first_posted>
  <last_update_submitted>October 27, 2014</last_update_submitted>
  <last_update_submitted_qc>October 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psyllium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

